Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 897122 | ISIN: FI0009900682 | Ticker-Symbol: VAYA
Frankfurt
08.11.24
09:15 Uhr
46,350 Euro
+0,300
+0,65 %
1-Jahres-Chart
VAISALA OYJ Chart 1 Jahr
5-Tage-Chart
VAISALA OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
46,75047,95010:33
GlobeNewswire (Europe)
226 Leser
Artikel bewerten:
(1)

Vaisala Group: Vaisala Corporation Half Year Financial Report January-June 2024

Vaisala Corporation Half Year Financial Report July 25, 2024, at 9:00 a.m. (EEST)

Vaisala Corporation Half Year Financial Report January-June 2024

Strong growth in Q2 orders received and net sales, operating result doubled

This release is a summary of Vaisala's Half Year Financial Report January-June 2024. The complete report is attached to this release as a pdf file. It is also available on the company website at www.vaisala.com/investors.

Second quarter 2024 highlights

  • Orders received EUR 147.2 (129.3) million, increase 14%
  • Order book at the end of the period EUR 196.9 (167.4) million, increase 18%
  • Net sales EUR 148.4 (130.8) million, increase 13%
  • Operating result (EBIT) EUR 23.7 (11.9) million, 15.9 (9.1) % of net sales
  • Earnings per share EUR 0.49 (0.22)
  • Cash flow from operating activities EUR 7.7 (8.8) million

January-June 2024 highlights

  • Orders received EUR 270.5 (261.3) million, increase 4%
  • Net sales EUR 260.5 (262.6) million, decrease 1%
  • Operating result (EBIT) EUR 30.8 (25.2) million, 11.8 (9.6) % of net sales
  • Earnings per share EUR 0.64 (0.49)
  • Cash flow from operating activities EUR 24.8 (35.7) million

Business outlook for 2024 - estimate ranges specified

Vaisala estimates that its full-year 2024 net sales will be in the range of EUR 540-570 million and its operating result (EBIT) will be in the range of EUR 68-78 million.

Earlier Vaisala estimated that its full-year 2024 net sales would be in the range of EUR 530-570 million and its operating result (EBIT) would be in the range of EUR 63-78 million.

Market outlook for 2024

Markets for high-end industrial instruments and life science slowed down significantly during Q2/2023 and remained on a lower level for the rest of the year. Markets remained flat in H1/2024 and are expected to start improving during H2/2024. Markets for power and energy, and liquid measurements markets are expected to grow.

Markets for the more mature markets, meteorology, aviation, and roads, are expected to be stable. Market for renewable energy is expected to grow.

Key figures

MEUR4-6/20244-6/2023Change1-6/20241-6/2023Change1-12/2023
Orders received147.2129.314%270.5261.34%528.1
Order book196.9167.418%196.9167.418%172.5
Net sales148.4130.813%260.5262.6-1%540.4
Gross profit84.672.117%145.3146.00%301.7
Gross margin, %57.055.1 55.855.6 55.8
Operating expenses61.260.41%114.8121.1-5%235.9
Operating result23.711.9 30.825.2 66.6
Operating result, %15.99.1 11.89.6 12.3
Result before taxes23.210.5 29.822.9 63.1
Result for the period17.98.0 23.117.6 48.9
Earnings per share0.490.22124%0.640.4931%1.35
Return on equity, % 17.414.5 18.9
Research and development costs17.918.1-1%34.336.0-5%67.7
Capital expenditure4.93.634%6.96.72%13.9
Depreciation, amortization, and impairment5.86.1-4%11.512.0-4%24.3
Cash flow from operating activities7.78.8-13%24.835.7-31%83.8
Cash and cash equivalents 65.251.227%90.3
Interest-bearing liabilities 45.962.9-27%62.1
Gearing, % -7.34.9 -10.5

President and CEO Kai Öistämö

"Vaisala had a strong second quarter and both our business areas performed well after the slow start of the year. We continued executing our strategy with sustained profitability improvement in the established weather business and continued growth in subscription sales as well as in services sales. Compared to the previous year, our Q2 orders received grew by 14% and net sales by 13%. The quarter ended with a new record-high order book of EUR 197 million. Moreover, our Q2 operating result more than doubled compared to the previous year, reflecting the strong growth in net sales, improved gross margin, and successful cost consciousness.

After challenging 12 months, Industrial Measurements business area was back on growth. Q2 orders received grew by 8% and net sales by 7%. In the life science market segment, orders received were at previous year's level, while orders in all other market segments grew. Net sales continued to grow very strongly in the power and energy market segment. We saw very strong growth also in the business area's service sales, resulting from systematic sales efforts and growing the installed base of our equipment. The gross margin and operating result margin returned to a good level, operating result margin again exceeding 20%.

For Weather and Environment business area, Q2 was very strong in all aspects. Both orders received and net sales grew by 18%. Orders received grew especially in the aviation and meteorology market segments, and net sales grew in all market segments. Net sales growth was mainly driven by large orders received during the past quarters and high project sales during the quarter. The subscription sales business continued to grow at a very strong growth rate of 16%. The operating result more than doubled compared to previous year and was 12.2% of net sales.

In June, our new Chief Digital and Information Officer Girish Agarwal joined the company. Girish brings strong expertise in advanced AI, IT, and digitalization, which are key areas for our future success. He succeeds Olli Nastamo, who retires after a long and successful career. I want to thank Olli for his contributions and warmly welcome Girish to our team.

Looking forward, our view on the full year 2024 remains unchanged, but after H1 solid performance, we have narrowed our estimate ranges for the full-year net sales and operating result. We anticipate that the business environment remains uncertain, and we need to continue to pace our investments accordingly. However, we continue to anticipate that our performance in the second half of the year will be stronger than in the first half. We now estimate that our full-year 2024 net sales will be in the range of EUR 540-570 million and operating result (EBIT) in the range of EUR 68-78 million."

Audiocast and teleconference
An audiocast and a conference call for analysts, investors and media will be held in English on Thursday 25, 2024, starting at 1:30 p.m. (Finnish time).

You can participate in the live audiocast via following link: https://vaisala.videosync.fi/q2-2024/register

Questions may be presented by participating in the teleconference. You can access the teleconference by registering on the link below. After the registration, you will receive an email with the dial-in numbers and a conference ID.
https://palvelu.flik.fi/teleconference/?id=50048552

A recording will be available at Vaisala.com/investors later the same day.

Further information
Paula Liimatta
+358 9 8949 2020, ir@vaisala.com
Vaisala Corporation

Distribution
Nasdaq Helsinki
Key media
vaisala.com

Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of over 2,300 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange. vaisala.com

Attachment

  • Vaisala Half Year Financial Report 2024 (https://ml-eu.globenewswire.com/Resource/Download/016f7e3b-9fec-4dbd-a0df-e136f57c417f)

© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.